These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

258 related items for PubMed ID: 17483015

  • 1. Does a delay in initiating definitive therapy affect biochemical recurrence rates in men with clinically localized prostate cancer?
    Phillips JJ, Hall MC, Lee WR, Clark PE.
    Urol Oncol; 2007; 25(3):196-200. PubMed ID: 17483015
    [Abstract] [Full Text] [Related]

  • 2. Association of percent positive prostate biopsies and perineural invasion with biochemical outcome after external beam radiotherapy for localized prostate cancer.
    Wong WW, Schild SE, Vora SA, Halyard MY.
    Int J Radiat Oncol Biol Phys; 2004 Sep 01; 60(1):24-9. PubMed ID: 15337536
    [Abstract] [Full Text] [Related]

  • 3. Biochemical (prostate specific antigen) recurrence probability following radical prostatectomy for clinically localized prostate cancer.
    Han M, Partin AW, Zahurak M, Piantadosi S, Epstein JI, Walsh PC.
    J Urol; 2003 Feb 01; 169(2):517-23. PubMed ID: 12544300
    [Abstract] [Full Text] [Related]

  • 4. Prostate-specific antigen doubling time predicts clinical outcome and survival in prostate cancer patients treated with combined radiation and hormone therapy.
    Lee AK, Levy LB, Cheung R, Kuban D.
    Int J Radiat Oncol Biol Phys; 2005 Oct 01; 63(2):456-62. PubMed ID: 15927415
    [Abstract] [Full Text] [Related]

  • 5. Improved biochemical relapse-free survival with increased external radiation doses in patients with localized prostate cancer: the combined experience of nine institutions in patients treated in 1994 and 1995.
    Kupelian P, Kuban D, Thames H, Levy L, Horwitz E, Martinez A, Michalski J, Pisansky T, Sandler H, Shipley W, Zelefsky M, Zietman A.
    Int J Radiat Oncol Biol Phys; 2005 Feb 01; 61(2):415-9. PubMed ID: 15667961
    [Abstract] [Full Text] [Related]

  • 6. Reasonable delay of surgical treatment in men with localized prostate cancer--impact on prognosis?
    Graefen M, Walz J, Chun KH, Schlomm T, Haese A, Huland H.
    Eur Urol; 2005 Jun 01; 47(6):756-60. PubMed ID: 15925069
    [Abstract] [Full Text] [Related]

  • 7. Patterns of local failure following prostate brachytherapy.
    Stone NN, Stock RG, White I, Unger P.
    J Urol; 2007 May 01; 177(5):1759-63; duscussion 1763-4. PubMed ID: 17437808
    [Abstract] [Full Text] [Related]

  • 8. Perineural invasion affects biochemical recurrence-free survival in patients with prostate cancer treated with definitive external beam radiotherapy.
    Yu HH, Song DY, Tsai YY, Thompson T, Frassica DA, DeWeese TL.
    Urology; 2007 Jul 01; 70(1):111-6. PubMed ID: 17656219
    [Abstract] [Full Text] [Related]

  • 9. Adjuvant radiotherapy in prostate cancer: predictors of prostate-specific antigen recurrence from the CaPSURE database.
    Macdonald OK, D'Amico AV, Sadetsky N, Shrieve DC, Carroll PR.
    Urology; 2007 Jul 01; 70(1):106-10. PubMed ID: 17656218
    [Abstract] [Full Text] [Related]

  • 10. Clinical and pathological characteristics, and recurrence rates of stage T1c versus T2a or T2b prostate cancer.
    Ramos CG, Carvalhal GF, Smith DS, Mager DE, Catalona WJ.
    J Urol; 1999 May 01; 161(5):1525-9. PubMed ID: 10210388
    [Abstract] [Full Text] [Related]

  • 11. [Biochemical monitoring of prostate cancer treated exclusively by radiotherapy: prognostic value of pretreatment PSA, PSA nadir and PSA half-life].
    Chautard D, Cellier P, Dalifard I, Pabot du Chatelard P, Chaussis F, Vielle B, Soret JY, Passagot J, Courte C, Daver A.
    Prog Urol; 2002 Jun 01; 12(3):421-8. PubMed ID: 12189749
    [Abstract] [Full Text] [Related]

  • 12. What pretreatment prostate-specific antigen level warrants long-term androgen deprivation?
    Feigenberg SJ, Hanlon AL, Horwitz EM, Uzzo RG, Eisenberg DF, Pollack A.
    Int J Radiat Oncol Biol Phys; 2005 Mar 15; 61(4):1003-10. PubMed ID: 15752879
    [Abstract] [Full Text] [Related]

  • 13. Percentage of positive biopsy cores, preoperative prostate-specific antigen (PSA) level, pT and Gleason score as predictors of PSA recurrence after radical prostatectomy: a multi-institutional outcome study in Japan.
    Yokomizo A, Murai M, Baba S, Ogawa O, Tsukamoto T, Niwakawa M, Tobisu K, Kinukawa N, Naito S.
    BJU Int; 2006 Sep 15; 98(3):549-53. PubMed ID: 16925752
    [Abstract] [Full Text] [Related]

  • 14. Does the time from biopsy to surgery affect biochemical recurrence after radical prostatectomy?
    Boorjian SA, Bianco FJ, Scardino PT, Eastham JA.
    BJU Int; 2005 Oct 15; 96(6):773-6. PubMed ID: 16153197
    [Abstract] [Full Text] [Related]

  • 15. Limited pelvic lymph node dissection does not improve biochemical relapse-free survival at 10 years after radical prostatectomy in patients with low-risk prostate cancer.
    Weight CJ, Reuther AM, Gunn PW, Zippe CR, Dhar NB, Klein EA.
    Urology; 2008 Jan 15; 71(1):141-5. PubMed ID: 18242383
    [Abstract] [Full Text] [Related]

  • 16. Effect of obesity on prostate-specific antigen recurrence after radiation therapy for localized prostate cancer as measured by the 2006 Radiation Therapy Oncology Group-American Society for Therapeutic Radiation and Oncology (RTOG-ASTRO) Phoenix consensus definition.
    Stroup SP, Cullen J, Auge BK, L'Esperance JO, Kang SK.
    Cancer; 2007 Sep 01; 110(5):1003-9. PubMed ID: 17614338
    [Abstract] [Full Text] [Related]

  • 17. Prognostic value of preoperative serum cell-free circulating DNA in men with prostate cancer undergoing radical prostatectomy.
    Bastian PJ, Palapattu GS, Yegnasubramanian S, Lin X, Rogers CG, Mangold LA, Trock B, Eisenberger M, Partin AW, Nelson WG.
    Clin Cancer Res; 2007 Sep 15; 13(18 Pt 1):5361-7. PubMed ID: 17875764
    [Abstract] [Full Text] [Related]

  • 18. Time trends in case selection, stage and prostate-specific antigen recurrence after radical prostatectomy: a multicentre audit.
    Winkler MH, Khan FA, Hoh IM, Okeke AA, Sugiono M, McInerney P, Boustead GB, Persad R, Kaisary AV, Gillatt DA.
    BJU Int; 2004 Apr 15; 93(6):725-9. PubMed ID: 15049980
    [Abstract] [Full Text] [Related]

  • 19. Six-month androgen suppression plus radiation therapy compared with radiation therapy alone for men with prostate cancer and a rapidly increasing pretreatment prostate-specific antigen level.
    D'Amico AV, Loffredo M, Renshaw AA, Loffredo B, Chen MH.
    J Clin Oncol; 2006 Sep 01; 24(25):4190-5. PubMed ID: 16943536
    [Abstract] [Full Text] [Related]

  • 20. Neoadjuvant hormone therapy and external-beam radiation for localized high-risk prostate cancer: the importance of PSA nadir before radiation.
    Ludgate CM, Bishop DC, Pai H, Eldridge B, Lim J, Berthelet E, Blood P, Piercy GB, Steinhoff G.
    Int J Radiat Oncol Biol Phys; 2005 Aug 01; 62(5):1309-15. PubMed ID: 16029786
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.